The American Society of Hematology (ASH) Annual Meeting will take place Dec. 7 through Dec. 10 in Orlando, Florida, and the abstracts for the meeting—always eagerly awaited—were released yesterday. Among the over 700 abstracts dealing with or mentioning myeloma, it is extremely difficult to highlight just 10 of interest. This year, 92 abstracts were selected for oral presentation and there is a clear preference for the high-profile, new, and emerging immune therapies, including CAR T-cell approaches. This should not distract from the huge poster sessions on Saturday, Dec. 7, Sunday, Dec. 8, and Monday, Dec. 9, which include numerous new and important reports. These will be a source of many “takeaways” from ASH when we have a chance to see full details. In the meantime, I will preview some of the top oral presentations which focus on new observations that may have an impact on the future of myeloma care.